<DOC>
	<DOCNO>NCT00095342</DOCNO>
	<brief_summary>The primary objective clinical research study compare efficacy safety 3 dose level oral TMI-005 comparison placebo subject active Rheumatoid Arthritis ( RA ) receive stable dos Methotrexate ( MTX ) .</brief_summary>
	<brief_title>Study Evaluating TMI-005 Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Meet American College Rheumatology ( ACR ) criteria RA Have active RA Disease duration least 6 month Disease onset &gt; 16 year age . Any prior use antiTNF alpha biologics , rituximab , receipt antiCD4 diphtheria interleukin2 fusion protein immunosuppressive biologics ( except anakinra ) Largely wholly incapacitated subject bedridden confine wheelchair , permit limited selfcare Pregnant breastfeed woman woman plan become pregnant study within 12 week last dose test article</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>